A Stock You Should Be Looking At: Clover Health Investments Corp. (NASDAQ:CLOV)

The price of Clover Health Investments Corp. (NASDAQ: CLOV) closed at $1.25 in the last session, up 0.81% from day before closing price of $1.24. In other words, the price has increased by $+0.0100 from its previous closing price. On the day, 3735043 shares were traded. CLOV stock price reached its highest trading level at $1.2659 during the session, while it also had its lowest trading level at $1.2100.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored

Ratios:

We take a closer look at CLOV’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.30 and its Current Ratio is at 1.30. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.05.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Cowen on February 02, 2022, Upgraded its rating to Market Perform and sets its target price to $3 from $7 previously.

On February 02, 2022, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $6.

On January 19, 2022, SVB Leerink started tracking the stock assigning a Mkt Perform rating and target price of $3.SVB Leerink initiated its Mkt Perform rating on January 19, 2022, with a $3 target price.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 11 when SHAPIRO LEE bought 80,000 shares for $3.10 per share. The transaction valued at 248,072 led to the insider holds 107,100 shares of the business.

Clinton Chelsea bought 100,000 shares of CLOV for $252,530 on Mar 03. The Director now owns 100,000 shares after completing the transaction at $2.53 per share.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 0.19 while its Price-to-Book (P/B) ratio in mrq is 1.52.

Stock Price History:

Over the past 52 weeks, CLOV has reached a high of $5.78, while it has fallen to a 52-week low of $1.21. The 50-Day Moving Average of the stock is 1.6700, while the 200-Day Moving Average is calculated to be 2.4810.

Shares Statistics:

According to the various share statistics, CLOV traded on average about 7.44M shares per day over the past 3-months and 8.77M shares per day over the past 10 days. A total of 477.69M shares are outstanding, with a floating share count of 346.36M. Insiders hold about 3.10% of the company’s shares, while institutions hold 32.50% stake in the company. Shares short for CLOV as of Oct 13, 2022 were 31.96M with a Short Ratio of 30.95M, compared to 35.24M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 6.69% and a Short% of Float of 8.34%.

Earnings Estimates

The company has 5 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.24 for the current quarter, with a high estimate of -$0.15 and a low estimate of -$0.36, while EPS last year was -$0.08. The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.15 and low estimates of -$0.42.

Analysts are recommending an EPS of between -$0.62 and -$1.16 for the fiscal current year, implying an average EPS of -$0.88. EPS for the following year is -$0.7, with 5 analysts recommending between -$0.43 and -$0.89.

Revenue Estimates

According to 5 analysts, the current quarter’s revenue is expected to be $799.46M. It ranges from a high estimate of $836.51M to a low estimate of $736.01M. As of the current estimate, Clover Health Investments Corp.’s year-ago sales were $427.16M, an estimated increase of 87.20% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $782.96M, an increase of 81.20% less than the figure of $87.20% in the same quarter last year. There is a high estimate of $829.12M for the next quarter, whereas the lowest estimate is $728.2M.

A total of 6 analysts have provided revenue estimates for CLOV’s current fiscal year. The highest revenue estimate was $3.38B, while the lowest revenue estimate was $3.19B, resulting in an average revenue estimate of $3.31B. In the same quarter a year ago, actual revenue was $1.47B, up 124.80% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $4.04B in the next fiscal year. The high estimate is $4.47B and the low estimate is $3.65B. The average revenue growth estimate for next year is up 22.00% from the average revenue estimate for this year.